-
公开(公告)号：AU2010321830B2
公开(公告)日：2015-06-11
申请号：AU2010321830
申请日：2010-11-19
Applicant: ACADEMIA SINICA
Inventor： LIANG SHU-MEI , CHIU CHING-FENG , HUNG SHAO-WEN , PENG JEI-MING , LIANG CHI-MING
Abstract: Methods are provided for suppressing cancer metastasis. Cancer metastasis is the most common cause of treatment failure and death in cancer patients. Tumor cell invasion and/or migration can be significantly inhibited after fibrillar proteins (rVP1, F-HSA, and F-BSA) treatment
-
公开(公告)号：AU2010321830A1
公开(公告)日：2012-07-05
申请号：AU2010321830
申请日：2010-11-19
Applicant: ACADEMIA SINICA
Inventor： LIANG SHU-MEI , CHIU CHING-FENG , HUNG SHAO-WEN , PENG JEI-MING , LIANG CHI-MING
Abstract: Methods are provided for suppressing cancer metastasis. Cancer metastasis is the most common cause of treatment failure and death in cancer patients. Tumor cell invasion and/or migration can be significantly inhibited after fibrillar proteins (rVP1, F-HSA, and F-BSA) treatment . In addition, rVP1 can significantly suppress murine and human breast cancer metastasis and human prostate and ovarian cancer metastasis while F-HSA can significantly suppress murine breast cancer metastasis. Compositions of fibrillar proteins as anti-cancer metastasis therapeutics and methods of use thereof are provided herein.
-
公开(公告)号：CA2781433C
公开(公告)日：2019-04-09
申请号：CA2781433
申请日：2010-11-19
Applicant: ACADEMIA SINICA
Inventor： LIANG SHU-MEI , CHIU CHING-FENG , HUNG SHAO-WEN , PENG JEI-MING , LIANG CHI-MING
Abstract: Methods are provided for suppressing cancer metastasis. Cancer metastasis is the most common cause of treatment failure and death in cancer patients. Tumor cell invasion and/or migration can be significantly inhibited after fibrillar proteins (rVP1, F-HSA, and F-BSA) treatment in vitro. In addition, rVP1 can significantly suppress murine and human breast cancer metastasis and human prostate and ovarian cancer metastasis in vivo while F-HSA can significantly suppress murine breast cancer metastasis. Compositions of fibrillar proteins as anti-cancer metastasis therapeutics and methods of use thereof are provided herein.
-
4.发明专利
公开(公告)号：GB2464028B
公开(公告)日：2011-06-01
申请号：GB201000660
申请日：2008-05-30
Applicant: ACADEMIA SINICA
Inventor： LIANG SHU-MEI , HUANG CHUN-YUNG , LIANG CHI-MING
-
公开(公告)号：CA2781433A1
公开(公告)日：2011-05-26
申请号：CA2781433
申请日：2010-11-19
Applicant: ACADEMIA SINICA
Inventor： LIANG SHU-MEI , CHIU CHING-FENG , HUNG SHAO-WEN , PENG JEI-MING , LIANG CHI-MING
Abstract: Methods are provided for suppressing cancer metastasis. Cancer metastasis is the most common cause of treatment failure and death in cancer patients. Tumor cell invasion and/or migration can be significantly inhibited after fibrillar proteins (rVP1, F-HSA, and F-BSA) treatment in vitro. In addition, rVP1 can significantly suppress murine and human breast cancer metastasis and human prostate and ovarian cancer metastasis in vivo while F-HSA can significantly suppress murine breast cancer metastasis. Compositions of fibrillar proteins as anti-cancer metastasis therapeutics and methods of use thereof are provided herein.
-
Patent Agency Ranking
公开(公告)号：GB2460966B
公开(公告)日：2010-05-19
申请号：GB0913559
申请日：2008-05-30
Applicant: ACADEMIA SINICA
Inventor： HUANG CHUN-YUNG , LIANG SHU-MEI , LIANG CHI-MING
Abstract: A conserved cluster of oligomannose glycans on gp120 has been identified as the epitope recognized by the broadly HIV-1-neutralizing monoclonal antibody 2G12. Oligomannose glycans are also the ligands for DC-SIGN, a C-type lectin found on the surface of dendritic cells. Multivalency is fundamental for carbohydrate-protein interactions, and mimicking of the high glycan density on the virus surface has become essential for designing carbohydrate-based HIV vaccines and antiviral agents. Synthesis of oligomannose dendrons, which display multivalent oligomannoses in high density, and characterize their interaction with 2G12 and DC-SIGN by a glycan microarray binding assay is disclosed. These glycodendrons inhibit the binding of gp120 to 2G12 and recombinant dimeric DC-SIGN with IC50 in the nanomolar range. A second-generation Man9 dendron was identified as a potential immunogen for HIV vaccine development and as a potential antiviral agent.
-
公开(公告)号：GB2460283B
公开(公告)日：2010-04-21
申请号：GB0809919
申请日：2008-05-30
Applicant: ACADEMIA SINICA
Inventor： LIANG SHU-MEI , HUANG CHUN-YUNG , LIANG CHI-MING
Abstract: A conserved cluster of oligomannose glycans on gp120 has been identified as the epitope recognized by the broadly HIV-1-neutralizing monoclonal antibody 2G12. Oligomannose glycans are also the ligands for DC-SIGN, a C-type lectin found on the surface of dendritic cells. Multivalency is fundamental for carbohydrate-protein interactions, and mimicking of the high glycan density on the virus surface has become essential for designing carbohydrate-based HIV vaccines and antiviral agents. Synthesis of oligomannose dendrons, which display multivalent oligomannoses in high density, and characterize their interaction with 2G12 and DC-SIGN by a glycan microarray binding assay is disclosed. These glycodendrons inhibit the binding of gp120 to 2G12 and recombinant dimeric DC-SIGN with IC50 in the nanomolar range. A second-generation Man9 dendron was identified as a potential immunogen for HIV vaccine development and as a potential antiviral agent.
-
公开(公告)号：AU2015287696A1
公开(公告)日：2017-02-16
申请号：AU2015287696
申请日：2015-07-10
Applicant: ACADEMIA SINICA
Inventor： HSIEH PATRICK CH , WU PEI-JUNG , ROFFLER STEVE , CHENG BILL , LIANG CHI-MING
Abstract: Disclosed herein is a multiple drugs delivery system and its uses in treating diseases. The multiple drugs delivery system includes, an anti-PEG antibody for directing the PEGylated therapeutic to the treatment site; and a hydrogel for retaining the anti-PEG antibody and/or the PEGylated therapeutic at the treatment site for at least 3 days. The hydrogel is selected from the group consisting of hyaluronan (HA) or a derivative of HA, collagen, gelatin, fibronectin, fibrinogen, alginate, chitosan, and a synthetic biocompatible polymer. The anti-PEG antibody and the hydrogel are present in the mixture in a ratio from about 1:1 (v/v) to 1:100 (v/v). At least two dosages of the PEGylated therapeutic, which may be the same or different, are administered to the subject, with each dosage being given at about 1 hour to about 1 week apart. Accordingly, a novel method of treating a subject having cancer or ischemia disease is also provided.
-
9.发明专利
公开(公告)号：GB2464028A
公开(公告)日：2010-04-07
申请号：GB201000660
申请日：2008-05-30
Applicant: ACADEMIA SINICA
Inventor： LIANG SHU-MEI , HUANG CHUN-YUNG , LIANG CHI-MING
Abstract: An isolated fibrillar structure protein of the foot-and-mouth-disease virus, selected from recombinant capsid protein VP1 (rVP1), recombinant capsid protein VP2 (rVP2), recombinant capsid protein VP3 (rVP3), precursor protein P1 of VP1, VP2, VP3 and VP4, or a chimeric protein comprising parts of at least two proteins selected from VP1, VP2, VP3 or VP4. Also disclosed is the use of this isolated fibrillar structure protein of the foot-and-mouth-disease virus in medicine, in particular in the treatment of cancer, and a pharmaceutical composition comprising said protein.
-
公开(公告)号：GB2460283A
公开(公告)日：2009-11-25
申请号：GB0809919
申请日：2008-05-30
Applicant: ACADEMIA SINICA
Inventor： LIANG SHU-MEI , HUANG CHUN-YUNG , LIANG CHI-MING
Abstract: The method comprising the steps of providing a globular protein, forming a solution containing the globular protein, adding a detergent to the solution containing the globular protein, and applying the solution to a molecular sizing column with a pore size of at least 70 kDa. The column is preferably selected from a SuperdexRTM200 or a HW555, and the detergent is preferably selected from SDS or Zwittergent 3-14. The globular protein is preferably selected from albumin, fibronectin or recombinant capsid proteins VP1, VP2, or VP3 of the foot and mouth disease virus, or precursor or chimeric proteins thereof. The proteins may have a use in medicine, particularly in the treatment of cancer, or they may be used as vaccine adjuvants.
-
-
-
-
-
-
-
-
-
Search Results
15
records
(took 0.029 seconds)
